Integrated DNA Technologies and Elegen partner to revolutionize long DNA synthesis market

Global genomics solutions leader Integrated DNA Technologies (IDT) and Elegen, the leader in next-generation DNA manufacturing, are teaming up to offer IDT customers early access to Elegen’s ENFINIA™ Plasmid DNA, a long and high-complexity clonal gene synthesis service. Through this partnership, IDT early access customers will, for the first time, have access to a cost-effective solution for NGS-verified 5 kb to 15 kb clonal genes, shipped from Elegen’s U.S. facility, in as fast as 10 business days.

The partnership strengthens IDT’s robust synthetic biology portfolio comprised of gene and gene fragments, including Rapid Genes, different vectors and plate formats for high-throughput workflows, and custom solutions support led by an innovative team of scientists and synthetic biology experts.

“IDT has continued to bolster its synthetic biology offerings and capabilities with new products and enhancements, as well as a U.S. facility expansion, to boost our throughput and efficiency over the last 12 months,” said Sandy Ottensmann, VP/General Manager, Gene Writing & Editing Business Unit at IDT. “Our partnership with Elegen allows us to offer customers competitively priced long and complex DNA that they can pair with IDT’s extensive portfolio of custom synthetic biology solutions.”

Matthew Hill, PhD, founder and CEO of Elegen, stated, “We are thrilled to partner with IDT, a long-standing leader in DNA synthesis. This collaboration allows Elegen to expand access to our ENFINIA^™ Plasmid DNA and equip researchers rapid access to longer and more complex DNA sequences—capabilities that have historically been limited in the market. We believe this partnership will accelerate research and development across the industry, driving innovation and breakthroughs in the life sciences.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>